Insider trading

Period: 12 months Stock: INCY Role: Other officers × Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

14 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

14 decisions over 12 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

14 decisions over 12 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

14 decisions over 12 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
14 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
14 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

14 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
15 Sep 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan 2×
$2.80M 23,218 at 120.49
11.2%
Planned (10b5-1)
19 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.36M 10,801 at 125.56
5.6%
Planned (10b5-1)
12 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.30M 10,803 at 120.04
5.3%
Planned (10b5-1)
5 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.31M 10,640 at 122.69
4.9%
Planned (10b5-1)
31 Jul 2026
Mayes Patrick A EVP & Chief Scientific Officer
Sold on a plan 11×
$5.01M 41,899 at 119.46
40.5%
Planned (10b5-1)
31 Jul 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.90M 15,888 at 119.70
6.9%
Planned (10b5-1)
15 Jul 2026
Stein Steven H CMO & Head of Late-Stage Dev.
Sold on a plan
$3.19M 28,237 at 113.05
52.0%
Sold half or more
17 Apr 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.80M 18,667 at 96.50
6.6%
Planned (10b5-1)
17 Mar 2026
CAGNONI PABLO J President, R&D
Sold on a plan
$1.76M 18,667 at 94.24
7.4%
Planned (10b5-1)
19 Feb 2026
CAGNONI PABLO J President, R&D
Sold on a plan
$1.88M 18,668 at 100.91
7.4%
Planned (10b5-1)
7 Jan 2026
Issa Mohamed Khairie EVP, Head of US Oncology
Sold on a plan
$1.18M 10,856 at 109.07
14.1%
Planned (10b5-1)
5 Jan 2026
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$1.59M 15,634 at 101.70
31.4%
Planned (10b5-1)
16 Dec 2025
Morrissey Michael James EVP, Head of Tech. Operations
Sold on a plan 2×
$5.25M 54,008 at 97.29
62.9%
Sold half or more
2 Dec 2025
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$2.06M 20,105 at 102.51
24.2%
Planned (10b5-1)
Showing 1–14 of 14.